Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus
| Autor: | B. I. Rini, R. N. Salas, Ronald M. Bukowski, Jorge A. Garcia, Laura D. Wood, Paul Elson, Joanna Ireland, Jennifer S. Ko, James H. Finke |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty biology Sunitinib medicine.drug_class business.industry Cell urologic and male genital diseases medicine.disease Temsirolimus Tyrosine-kinase inhibitor Peripheral blood medicine.anatomical_structure Immune system Renal cell carcinoma Internal medicine embryonic structures cardiovascular system medicine biology.protein business Platelet-derived growth factor receptor medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 26:5099-5099 |
| ISSN: | 1527-7755 0732-183X |
| Popis: | 5099 Background: Sunitinib is an oral tyrosine kinase inhibitor of VEGFR-2, PDGFR, KIT, and FLT3 and a first line standard of care for mRCC. Temsirolimus, also approved for mRCC, is an analog of th... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|